Multiple Myeloma | Specialty

Daratumumab Plus Rd New Frontline Standard in Transplant-Ineligible Myeloma

December 4th 2018

The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Selinexor Induces Responses in a Quarter of Patients with Heavily Pretreated MM

December 4th 2018

A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.

Dr. Shah on Initial Results for bb21217 in Multiple Myeloma

December 4th 2018

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.

Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma

December 3rd 2018

The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.

Maintenance Ixazomib Extends PFS in Newly Diagnosed Multiple Myeloma

December 3rd 2018

Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.

Daratumumab Safe and Effective When Added to VRd in Newly Diagnosed MM

December 2nd 2018

Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.

ASH 2018: Dr. O'Connor Shares Insight on MCL and T-Cell Lymphoma Advances

December 1st 2018

ASH 2018: Dr. Wierda Discusses Pivotal Updates in CLL

December 1st 2018

ASH 2018: Dr. Landgren Highlights Pivotal Myeloma Data

December 1st 2018

Dr. Mesa Discusses Exciting Abstracts on Myeloproliferative Neoplasms

December 1st 2018

Dr. Pagel Highlights the Top Abstracts From the 2018 ASH Annual Meeting

December 1st 2018

Dr. Raje Discusses Investigational Treatment Strategies in Multiple Myeloma

December 1st 2018

Dr. Desai Discusses Advances in Treatment for Patients With AML

December 1st 2018

OncLive News Network On Location: In San Diego Monday, December 3

December 1st 2018

OncLive News Network On Location: In San Diego Sunday, December 2

December 1st 2018

OncLive News Network On Location: In San Diego Saturday, December 1

December 1st 2018

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

November 29th 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.

Myeloma Expert Previews 2018 ASH Abstracts

November 28th 2018

Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.

Current and Prospective Therapies Are Improving Outcomes in Relapsed Multiple Myeloma

November 24th 2018

During an OncLive Peer Exchange®, a panel of experts on multiple myeloma discussed new agents and combinations that are improving the care of patients with relapsed multiple myeloma and reviewed strategies for treating these patients when they develop drug resistance.

Unmet Needs and Final Thoughts on Myeloma

November 22nd 2018